REFERENCES
- SM Berge, LM Bighley, and DC Monkhouse. (1977). Pharmaceutical salts. J. Pharm. Sci 66 (1):1–19.
- CG Wermuth, and PH Stahl. Introduction Handbook of Pharmaceutical Salts: Properties, Selection and Use PH Stahl, and CG Wermuth. Wiley-VCH, Inc, Weinheim, (2002)1–7.
- BD Anderson, and RA Conradi. (1985). Predictive relationships in the water solubility of salts of a nonsteroidal anti-inflammatory drug. J. Pharm. Sci 74 (8):815–820.
- KR Morris, MG Fakes, AB Thakur, AW Newman, AK Singh, JJ Venit, CJ Spagnuolo, and ATM Serajuddin. (1994). An integrated approach to the selection of optimal salt form for a new drug candidate. Int. J. Pharm 105 (3):209–217.
- GL Engel, NA Farid, MM Faul, LA Richardson, and LL Winneroski. (2000). Salt form selection and characterization of LY333531 mesylate monohydrate. Int. J. Pharm 198 (2):239–247.
- DP Ip, and GS Brenner. Enalapril maleate. In: ed Analytical Profiles of Drug Substances K Florey. Academic Press, Inc, London, (1987)207–243.
- ML Cotton, DW Wu, and EB Vadas. (1987). Drug excipient interaction study of enalapril maleate using thermal analysis and scanning electron microscopy. Int. J. Pharm 40 (1–2):129–142.
- AMM Omari, MK Abdelah, AA Badwan, and AMY Jaber. (2001). Effect of the drug-matrix on the stability of enalapril maleate in tablet formulations. J. Pharm. Biomed. Anal 25 (5–6):893–902.
- F Janos, S Bela, B Attila, CG Mueller, F Tamas, L Sandor, and T Gabor. Salts of Enalpril . , , (2001) WO0132689..
- Soldato PD, U.S. Patent 6218417, ACE inhibitors nitric salts, (2001).
- WQ Tong, and G Whitesell. (1998). In situ salt screening – a useful technique for discovery support and preformulation studies. Pharm. Dev. Technol 3 (2):215–223.
- R Fürer, and M Geiger. (1976). A simple method of determining the aqueous solubility of organic substances. J. Pharm. Sci 8 (4):337–344.
- RL Carr. Classifying flow properties of solids Chem. Eng. . , , (1965)7269–72.
- RL Carr. Evaluation of flow properties of solids Chem. Eng. . , , (1965)72163–168.
- Ueda Y, Kinoshita K, Moroshima T, Yanagida Y, and Fuse Y. U.S. Patent 6335453, Process for preparing pharmacologically acceptable salt of N-(1(S)-ethoxycarbonyl-3-phenylpropyl)-L-alanyl amino acids, (2002).
- S Balbach, and C Korn. (2004). Pharmaceutical evaluation of early development candidates “the 100 mg-approach”.. Int. J. Pharm 275 (1–2):1–12.
- http://www. ich.org/LOB/media/MEDIA423.pdf ICH Harmonised Tripartite Guideline: Note for guidance on impurities – residual solvents Q3C (R3); 2005. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use.
- JC Callahan, JW Cleary, M Elefant, G Kaplan, T Kensler, and RA Nash. (1982). Equilibrium moisture content of pharmaceutical excipients. Drug Dev. Ind. Pharm 8 (3):355–369.
- SN Bhattachar, LA Deschenes, and JA Wesley. (2006). Solubility: It's not just for physical chemists. Drug Discov. Today 11 (21–22):1012–1018.
- GA Stephenson. (2005). Applications of X-ray powder diffraction in the pharmaceutical industry. Rigaku J 22 (1):2–15.
- M Karjalainen, S Airaksinen, J Rantanen, J Aaltonen, and J Yliruusi. (2005). Characterization of polymorphic solid-state changes using variable temperature x-ray powder diffraction. J. Pharm. Biomed. Anal 39 (1–2):27–32.
- MM de Villiers, RJ Terblanche, W Liebenberg, E Swanepoel, TG Dekker, and M Song. (2005). Variable-temperature x-ray powder diffraction analysis of the crystal transformation of the pharmaceutically preferred polymorph C of mebendazole. J. Pharm. Biomed. Anal 38 (3):435–441.
- NA Armstrong, and RF Haines-Nutt. (1972). Elastic recovery and surface area changes in compacted powder systems. J. Pharm. Pharmacol 24:135P–136.
- O Antikainen, and J Yliruusi. (2003). Determining the compression behavior of pharmaceutical powders from the force-distance compression profile. Int. J. Pharm 252 (1–2):253–261.
- C Sun, and DJW Grant. (2001). Influence of elastic deformation of particles on Heckel analysis. Pharm. Dev. Technol 6 (2):193–200.